Education
About Us
Working with TipRanks
Follow Us
DRI Healthcare (TSE:DHT.UN)
TSX:DHT.UN
Top Page
DRI Healthcare
(TSX:DHT.UN)
Select Model
Select Model
Rating:58Neutral
Price Target:
C$17.50
▲(0.06% Upside)
Action:ReiteratedDate:03/06/26
The score is held back most by weak and volatile financial statement quality (recent losses, negative free cash flow, and higher leverage). Offsetting this, the latest earnings call was upbeat with strong adjusted EBITDA/margins, cash receipts growth, and improved capital structure actions, while technicals are constructive and the dividend provides some support despite losses implied by the negative P/E.
Positive Factors
Recurring royalty cash flows
The royalty model delivers contractually defined, product-linked cash flows that persist for the life of each underlying drug franchise. This creates durable, revenue-linked receipts less tied to cyclical product development, supporting predictable distributions and underwriting of new acquisitions over multi-year horizons.
High and improving adjusted EBITDA margins
Record adjusted-EBITDA margins reflect successful internalization and cost synergies that raise cash conversion. Elevated margins are structural: internalization, lower cash costs, and portfolio scale improve long-run cash generation capacity and provide cushion for distributions and reinvestment even if headline net income varies.
Fully funded multi-year deployment plan
A funded $800M–$1B investment plan with explicit CAGR targets signals management confidence in origination and portfolio scaling. Fully funded commitments reduce execution funding risk, enabling durable growth in royalty income and supporting longer-term margin and cashflow targets through disciplined deployment and proven deal pipelines.
Negative Factors
Elevated and rising leverage
Leverage above 1.0 materially raises refinancing and covenant risk and reduces balance-sheet optionality when royalties underperform. With ROE turned negative, higher debt magnifies earnings volatility and could constrain capital deployment or force asset sales during adverse periods, weakening long-term financial flexibility.
Consistently negative and volatile free cash flow
Persistent negative free cash flow indicates that operating receipts are insufficient to cover capex, acquisitions or working capital needs without external financing. This pattern forces reliance on debt/equity markets for growth and distributions, increasing funding risk and undermining the sustainability of payouts during market stress.
Asset concentration and impairment risk
Concentration in a set of high-value royalties exposes cash flows to product-specific shocks, competition, and lifecycle cliffs. Large impairments and legacy declines show downside sensitivity: one-off write-downs and asymmetric accounting policies can produce durable volatility in reported earnings and pressure distributable cash when key assets underperform.
DRI Healthcare (DHT.UN) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$962.14M
Dividend Yield3.56%
Average Volume (3M)33.23K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue Growth-0.94%
EPS Growth-540.90%
CountryCA
Employees36
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.05
Shares Outstanding55,011,135
10 Day Avg. Volume43,025
30 Day Avg. Volume33,233
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.06
Price to Sales (P/S)2.38
P/FCF Ratio-40.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$21.00Price Target Upside20.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)3.17
Revenue Forecast (FY)C$266.71M
DRI Healthcare Business Overview & Revenue Model
Company DescriptionDRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
How the Company Makes MoneyDRI Healthcare generates revenue mainly through its investments in healthcare assets, which include royalties, licensing agreements, and equity stakes in pharmaceutical and biotech companies. The company earns revenue by receiving a percentage of sales from the products it invests in, particularly those that generate royalties from approved therapies. Additionally, DRI Healthcare may benefit from partnerships and collaborations with established firms in the healthcare sector, which can provide access to promising technologies and enhance its portfolio. The firm's focus on acquiring rights to innovative medical solutions allows it to capitalize on emerging trends in healthcare, contributing to its overall earnings.
DRI Healthcare Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call conveyed a predominately positive operational and financial story: record margins and adjusted EBITDA, cash receipt growth, successful capital allocation actions (unit buybacks, preferred redemptions, and longer-dated private placement debt), and outperformance from several recently acquired assets (Orserdu, Ekterly, Xempozyme). The company also outlined a funded growth plan through 2030 and a proprietary risk framework and AI integration to scale deal evaluation. Offsetting these positives are notable asset-specific headwinds (notably Omidria impairment, Vonjo and legacy product pressures), some lumpiness from one-time items, and a deliberate shift toward more pre‑approval deals that may slow near-term deployment pace. Overall, the highlights materially outweigh the lowlights, with management framing challenges clearly and taking actions to strengthen the balance sheet and underwriting process.Q4-2025 Updates
Positive Updates
Record Financial Performance and Margin Expansion
Total income of $198.6M for FY2025, up 6% year-over-year; normalized trailing 12-month adjusted EBITDA margin of 84% and normalized annual adjusted EBITDA margin of 88% (highest in company history); Q4 2025 adjusted EBITDA margin of 91% vs 83% in Q4 2024; trailing 12-month adjusted EBITDA of $165M.
Cash Receipts Growth
Normalized total cash receipts of $196.4M for the 12 months ending Dec 31, 2025, a $6.5M (3.4%) increase versus 2024; Q4 cash receipts up 14% quarter-over-quarter drivers cited in prepared remarks.
Exceeded 5-Year Deployment Target
Exceeded the 5-year deployment goal of $1.25B through upfront and committed capital deployments including the Viridian and Ekterly transactions, demonstrating strong origination and structuring capability.
Strong Performance from Key Assets (Orserdu, Ekterly, Xempozyme, Xolair, Casgevy)
Orserdu Q4 royalty receipts of $19M, a 38% YoY increase vs Q4 2024; Orserdu triggered a $5M milestone and Q1'26 receipts anticipated at ~$27M (≈$22M royalties + $5M milestone). Ekterly showed early traction with first receipts in 2025 and implied annual run rate >$140M from Q4 sales; Xempozyme Q4 receipts $2.5M with Sanofi reporting $71M Q4 and >$250M FY sales; Casgevy Q4 sales $54M and DRI to record a $5M license fee in Q1 2026; Xolair growth following food allergy launch.
Capital Allocation Actions and Unitholder Returns
Returned in excess of $36M to unitholders via unit repurchases and dividends in 2025; repurchased and canceled ~1.4M units in 2025 (reducing unit count by nearly 3%); aggregate repurchases of 4.6M units at an average price of $7.08 totaling $32.7M; increased quarterly distribution from $0.10 to $0.11 per unit (10% increase) beginning Q1 2026.
Balance Sheet and Financing Improvements
Redeemed/cancelled preferred shares ($10M face value for $9.5M and subsequent $9.9M for $9.8M plus accrued interest); negotiated swaps of majority remaining preferred into converts to reduce coupon and extend maturities; priced private placement debt to term out portion of bank facility to 5- and 7-year maturities; $239M of credit availability and $42.4M cash on hand as of Dec 31, 2025.
Operational Enhancements and Risk Framework
Completed internalization of the manager producing meaningful cost synergies and higher margins; established a proprietary data-driven risk assessment framework to guide deal selection, sizing and pricing; integrated AI into workflows with dedicated team members and internal compute to improve execution speed and quality.
Long-term Growth Targets and Funding Plan
2025 royalty income of $188.7M exceeded stated target range of $172M–$182M; management tracking a 12% royalty income CAGR off 2022 base (above prior high-single-digit target); plans to invest $800M–$1B from 2026–2030 (fully funded by current capital structure) with aspiration for low-teens adjusted EBITDA CAGR to 2030.
Negative Updates
Omidria Underperformance and Impairment
Omidria experienced prolonged softness driven by MIPS-related demand resets and lack of growth in HOPD; management took a $9.7M impairment in Q4 2025 and now forecasts flat sales/no growth for Omidria over the next few years.
Weakness in Several Legacy Assets
Softer performance from Oracea and Zytiga due to increased competition and generic entry; Rydapt is nearing the end of its royalty term with an expected step-down in royalty rate; Vonjo cash receipts declined 11% YoY in Q4 2025 and expectations for Vonjo were previously reduced.
Spinraza Pressure from Competition and Timing
Spinraza cash receipts were essentially flat YoY in Q4 2025 due to timing of shipments outside the U.S. and increased competition from Roche’s Evrysdi, limiting upside from this asset.
One-Time Items and Lumpy Comparisons
FY2024 and Q4 comparisons were impacted by one-time items (e.g., $18.2M back payment related to Orserdu in Q4 2024, $15.7M of which related to prior periods), creating lumpiness and making headline quarter-over-quarter comparisons uneven despite strong underlying trends (normalized Q4 total income up 35% YoY after adjusting for one-time items).
Deployment Pace and Portfolio Transition Risks
Management noted a strategic shift toward more pre‑approval (pre-commercial) deals; because pre-approval deals lack backward-looking cash flows, near-term deployment pacing may be slower over the next 12–24 months and could constrain leverage-driven deployment capacity despite attractive return profiles.
Conservative Recognition Policy and Downside-only Balance Sheet Adjustments
Company policy to never write up assets means balance sheet adjustments only capture negative revisions (impairments), creating asymmetric reported outcomes where outperformance is captured only in cash receipts/EBITDA and downside is reflected immediately in impairments.
Company Guidance
The guidance reflected meaningful growth versus the 2025 baseline (2025 total income $198.6M; royalty income $188.7M, above the $172–182M target; normalized cash receipts $196.4M; trailing 12‑month adjusted EBITDA $165M and margin 84% — normalized annual margin 88% — with Q4 margin at 91%), while acknowledging a $9.7M Q4 impairment on Omidria; the trust will raise the quarterly distribution to $0.11 (from $0.10) starting Q1 2026, expects to retain $42.4M cash, $59.7M royalties receivable and $239M of credit availability, and to realize >$25M of annual cash‑flow improvement from debt/preferred refinancings; longer term DRI plans $800M–$1B of investments in 2026–2030 (fully funded), targets a low‑teens CAGR in adjusted EBITDA through 2030 (currently tracking a 12% CAGR in royalty income off 2022), and expects remaining margin uplift of roughly 500 basis points versus pre‑internalization levels (each 1% of margin ≈ $2M of run‑rate cash flow).DRI Healthcare Financial Statement Overview
Summary
Strong revenue growth and consistently positive operating cash flow are positives, but overall quality is pressured by volatile profitability (large net loss and negative gross margin in 2025), persistently negative/free cash flow outflows, and rising leverage (debt-to-equity above 1.0 with ROE turning negative in 2024–2025).Income Statement
Revenue has grown strongly over the period (notably in 2022–2023, with continued growth in 2025), but profitability has become unstable. The latest annual period (2025) shows a large net loss and negative gross margin, despite a healthy EBITDA margin, suggesting significant non-core costs or accounting impacts. Results swung from strong profitability in 2023 to losses in 2024–2025, which weighs on quality and predictability of earnings.38
Negative
Balance Sheet
The balance sheet shows meaningful leverage that has risen recently: debt-to-equity increased from low levels earlier in the period to above 1.0 in 2025. Total assets remain sizable, but returns to shareholders deteriorated, with return on equity turning negative in 2024–2025 after being positive in 2021–2023. Strength is that equity remains substantial, but higher leverage and weakening returns increase financial risk.54
Neutral
Cash Flow
Operating cash flow has been positive each year from 2021–2025, which is a key support, but free cash flow is consistently negative and highly volatile (including very large outflows in 2023–2024). In 2025, operating cash flow covered net income (despite a loss), but free cash flow remained negative and fell sharply versus the prior year, pointing to ongoing cash investment requirements or unfavorable working-capital/capex dynamics.33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 195.17M | 138.55M | 117.44M | 79.87M | 73.33M |
| Gross Profit | -21.51M | 66.60M | -20.36M | 79.87M | 73.33M |
| EBITDA | 92.25M | -4.94M | 107.52M | 76.77M | 66.06M |
| Net Income | -51.35M | -3.36M | 91.50M | 11.60M | 21.56M |
Balance Sheet | |||||
| Total Assets | 941.10M | 984.87M | 833.16M | 633.42M | 436.69M |
| Cash, Cash Equivalents and Short-Term Investments | 42.35M | 36.50M | 62.84M | 36.69M | 61.71M |
| Total Debt | 482.06M | 432.12M | 145.48M | 244.99M | 43.92M |
| Total Liabilities | 503.32M | 457.34M | 273.46M | 261.08M | 57.71M |
| Stockholders Equity | 437.78M | 527.53M | 561.50M | 372.34M | 378.99M |
Cash Flow | |||||
| Free Cash Flow | -11.42M | -129.84M | -313.90M | -197.03M | -232.46M |
| Operating Cash Flow | 78.11M | 155.41M | 76.38M | 77.47M | 91.86M |
| Investing Cash Flow | -81.64M | -293.31M | -128.81M | -273.67M | -372.33M |
| Financing Cash Flow | 9.56M | 111.56M | 78.57M | 171.17M | 342.18M |
DRI Healthcare Technical Analysis
Positive
17.49
Price Trends
16.26
Positive
16.15
Positive
15.08
Positive
Market Momentum
0.24
Negative
63.91
Neutral
64.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHT.UN, the sentiment is Positive. The current price of 17.49 is above the 20-day moving average (MA) of 16.75, above the 50-day MA of 16.26, and above the 200-day MA of 15.08, indicating a bullish trend. The MACD of 0.24 indicates Negative momentum. The RSI at 63.91 is Neutral, neither overbought nor oversold. The STOCH value of 64.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DHT.UN.
DRI Healthcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$2.11B | 16.23 | 6.29% | ― | 6.18% | -28.69% | |
58 Neutral | C$962.14M | -9.05 | -10.92% | 3.56% | -0.94% | -540.90% | |
56 Neutral | C$1.65B | -13.95 | -9.71% | ― | 4.27% | 3.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$2.45B | -8.05 | -28.58% | ― | -3.38% | -31.35% | |
48 Neutral | C$2.17B | -1.75 | -30.10% | ― | -4.58% | -141.91% | |
45 Neutral | C$593.07M | -1.15 | -33.00% | ― | -6.48% | 22.63% |
* Healthcare Sector Average
TSE:DHT.UN
DRI Healthcare
17.49
6.22
55.16%
TSE:CURA
Curaleaf Holdings
3.16
1.72
119.44%
TSE:GTII
Green Thumb Industries
9.11
0.22
2.47%
TSE:TRUL
Trulieve Cannabis
8.56
2.75
47.33%
TSE:CL
Cresco Labs
1.34
0.31
30.10%
TSE:VRNO
Verano Holdings
6.32
0.00
0.00%
DRI Healthcare Corporate Events
Business Operations and StrategyStock BuybackDividendsFinancial DisclosuresPrivate Placements and Financing
DRI Healthcare Marks Record 2025 Results and Tightens Capital Structure for Multi-Year Growth
Positive
Mar 4, 2026
DRI Healthcare Trust reported a strong fourth quarter, generating total income of $61.7 million and an adjusted EBITDA margin of 91%, as internalizing its investment management function helped deliver record full-year total income, cash receipts, and adjusted EBITDA. For 2025, the trust committed over $1.25 billion of capital including future milestone payments, returned more than $36 million to unitholders, and set a higher 2026 quarterly distribution, while also absorbing impairments on certain royalty assets.
Management framed 2025 as an inflection point and said 2026 will be a foundational year for a new multi-year growth agenda, supported by the refinancing of preferred securities and the pricing of $250 million in senior secured notes to extend debt maturities and lower annual amortization. These financing moves, alongside continued portfolio deployment and unit buybacks, are aimed at strengthening the capital structure and supporting durable, compounding returns for unitholders over the long term.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$20.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
Business Operations and StrategyPrivate Placements and Financing
DRI Healthcare Trust Refinances Preferred Securities With New Convertible Debentures
Positive
Mar 2, 2026
DRI Healthcare Trust has struck a refinancing deal with EdgePoint Wealth Management Inc. and Alberta Investment Management Corporation, exchanging C$108.7 million of its 7.50% Series C preferred securities into new convertible unsecured subordinated debentures. The move extends the maturity of this portion of its capital structure to 2031 and lowers the interest rate to 5.75%, while leaving US$35.6 million of preferred securities outstanding.
The debentures, issued via a private placement and subject to a standard hold period, carry a 30% conversion premium with a C$21.99 unit conversion price and limited redemption rights before 2029. Management highlighted that the refinancing enhances financial flexibility and supports DRI Healthcare’s growth strategy, with closing targeted for mid-March subject to Toronto Stock Exchange approval and customary conditions.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$20.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
Financial Disclosures
DRI Healthcare Sets March 4 Call to Discuss 2025 Year-End Results
Neutral
Feb 11, 2026
DRI Healthcare Trust, a Toronto-based specialist in pharmaceutical royalty monetization, has built a diversified portfolio of more than 75 royalty interests on over 50 drugs, deploying in excess of $3.0 billion since 1989 and listing its units on the Toronto Stock Exchange in both Canadian and U.S. dollar denominations.
The company will release its fourth-quarter and full-year 2025 financial results after markets close on March 3, 2026, followed by a conference call and webcast on March 4, 2026, at 8:00 a.m. ET, signaling a forthcoming update on performance and portfolio developments that will be closely watched by equity analysts and investors.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$20.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.